4Q Revenues: $5.6 billion (+7%)
4Q Earnings: $771.8 million (+61%)
FY Revenues: $21.2 billion (+6%)
FY Earnings: $2.7 billion (+14%)
Comments: Growth for the year was primarily driven by Trulicity ($926 million, up from $249 million FY15) and other new pharmaceutical products, including Cyramza ($614 million up 60%), Jardiance ($202 million, up from $60 million FY15) and Taltz ($113 million), as well as Humalog ($2.8 billion, down 3%) and Erbitux ($687 million, up 42%, due to the transfer of commercialization rights in North America to Lilly). The volume increases were partially offset by the impact of the loss of exclusivity for Cymbalta (down 9% to $931 million) in Europe and Canada, Zyprexa (down 23% to $725 million) in Japan, and Alimta ($2.3 billion, down 8%) in several countries. Cialis sales were $2.5 billion, up 7%. In 2016, the company recognized an acquired in-process R&D charge of $30 million associated with the agreement with AstraZeneca to co-develop MEDI1814.